Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

BETHESDA, Md., March 13 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the fourth quarter and the full year ended December 31, 2007. As a result of the reverse merger between Micromet AG and CancerVax Corporation that was completed on May 5, 2006, the financial information included below for the fiscal year 2006 consists of Micromet AG's historical financial results for the period of January 1, 2006 to May 5, 2006 without the inclusion of the financial results of CancerVax, and the combined results of the two companies thereafter.

Summary of Recent Events:

-- Micromet published data on its BiTE(R) antibody MT103 at the annual

meeting of the American Society of Hematology in December, showing that

MT103 induces dose-dependent objective complete and partial responses

in late stage lymphoma patients. The BiTE antibody could also clear the

bone marrow and other infiltrated organs from tumor cells. Particularly

encouraging was the observation of complete responses in patients with

mantle cell lymphoma (MCL) -- a disease that is difficult to treat. In

Europe, Micromet has initiated a phase 2 study in acute lymphoblastic

leukemia, one of the most aggressive blood cancers.

-- Micromet has completed preclinical development for its second BiTE

antibody MT110. MT110 binds to EpCAM, a cell surface molecule that is

highly expressed on many solid tumors and on cancer stem cells -- those

cancer cells responsible for metasta
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... SAN FRANCISCO, Calif. , May 27, 2015 ... for the treatment of cancer, today announced the ... financial officer and Cynthia Ladd as ... joining CytomX, Goeltz was chief financial officer of ... served as an independent consultant and legal counsel ...
(Date:5/27/2015)... Mass. , May 27, 2015  RXi ... company focused on discovering and developing innovative therapies ... today provided an update on the status of the ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... were 3,085 and 21 shares of Series A ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 WORMS, ... Grace & Co. (NYSE: GRA) announces that its ... manufacturing practice (GMP) certification from EXCiPACTâ„¢, an independent ... pharmaceutical excipients. , All three Grace ... pharmaceutical grade excipient silica gels have now received ...
(Date:5/26/2015)... --  Intrexon Corporation (NYSE: XON ), a leader ... Ph.D., Senior Vice President and Head of Intrexon,s Health Sector, ... Wednesday, June 3 rd , at 1:30 p.m. Eastern Time ... . About Intrexon Corporation Intrexon ... with Better DNA ™ to create biologically-based products that ...
Breaking Biology Technology:CytomX Expands Executive Leadership Team 2CytomX Expands Executive Leadership Team 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Intrexon to Present at the Jefferies 2015 Global Healthcare Conference 2
... ISBT 128-compliant label,design and printing software solutions to healthcare providers, blood ... ... 28 Niceware(R) International, LLC is,excited to announce that ICCBBA, Inc. ... bag labeling,software solutions that support ISBT 128-compliant data structures and bar,codes. ...
... With 3.8 Million Patients Under Treatment, -- Diabetes ... ... Shareholders in ... 2008, FRANKLIN LAKES, N.J. and WAKEFIELD, Mass., Aug. 28 ,Medco Health Solutions, Inc. (NYSE: ...
... received in September 2007 for successful completion of ... Phase 2b clinical ... (Nasdaq: HGSI ) today announced that it will receive a ... completion of a Phase 2b trial of Albuferon(R) (albinterferon,alfa-2b) in treatment-naive ...
Cached Biology Technology:Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software 2Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 2Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 3Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 4Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 5Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 6Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 7Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development 2Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development 3Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development 4
(Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
(Date:4/27/2015)... more than four decades, AUVSI,s Unmanned Systems ... event for the unmanned land, sea, and air industries. ... local, national, or trade news organization interested in gathering ... applications of unmanned technologies. The conference will explore the ... and how it will soon impact the lives of ...
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... shows numerous characteristics that are common with a recently identified ... between the ages of 6 and 8. These results ... . Bisphenol A (BPA) is a chemical compound used ... for example to manufacture food containers such as bottles or ...
... dairy organizations from around the world are joining ... dairy at a symposium on "Maintaining health with ... prevention of metabolic syndrome, cardiovascular disease (CVD), obesity ... 20th International Union of Nutritional Science (IUNS) Congress ...
... 10, 2013   EyeLock Inc. , a market leader of iris-based ... Fast IDentity Online Alliance (FIDO) , to spearhead an ... for consumers.  EyeLock will collaborate with Alliance ... and Validity, among others, to identify and set a ...
Cached Biology News:Early exposure to bisphenol A might damage the enamel of teeth 2First international collaboration to showcase latest body of evidence of dairy health benefits 2Iris Biometrics Leader EyeLock Joins the FIDO Alliance to Help Identify More Secure Replacement for Usernames and Passwords 2Iris Biometrics Leader EyeLock Joins the FIDO Alliance to Help Identify More Secure Replacement for Usernames and Passwords 3
... Unique, compact measuring instrument for calibrating single-channel ... design and the robust carrying case, the ... in the laboratory and on-site at the ... to use because the individual channels are ...
... DTT White solid.. PACKAGED UNDER INERT ... so reaction is "driven" to completion. A protective ... surfactant found in many other preparations. Blocks the ... ≥97% by titration. Contaminants: Heavy metals: ...
... Whole Genome ChIP-on-chip Microarray is specifically ... (S. cerevisiae) DNA binding proteins by ... DNA microarrays. This set delivers robust ... greater true binding events and fewer ...
... Basically, most ``special`` dye stains ... a few other non-routine) stains are ... of a paraffin block, staining, coverslipping ... Stain (for senile plaques) ,Bodian`s Stain ...
Biology Products: